WARNING: QT PROLONGATION and SUDDEN DEATHS See full prescribing information for complete boxed warning. Tasigna prolongs the QT interval. Prior to Tasigna administration and periodically, monitor for hypokalemia or hypomagnesemia and correct deficiencies. Obtain ECGs to monitor the QTc at baseline, seven days after initiation, and periodically thereafter, and following any dose adjustments., Sudden deaths have been reported in patients receiving Tasigna. Do not administer Tasigna to patients with hypokalemia, hypomagnesemia, or long QT syndrome., Avoid use of concomitant drugs known to prolong the QT interval and strong CYP3A4 inhibitors., Avoid food 2 hours before and 1 hour after taking the dose. Tasigna may interact with certain medications that can cause serious and life-threatening effects. Before you start treatment with Tasigna, tell your doctor about any medications you take, including prescription, over-the-counter, herbal supplements, and vitamins., Be sure to discuss any allergies you may have with your doctor. Tasigna may contain ingredients that can cause an allergic reaction in those with an allergy., Tasigna can increase your risk for myelosuppression, cardiac and arterial vascular occlusive events, pancreatitis, liver problems, and electrolyte abnormalities. While you are taking Tasigna, your doctor will monitor your heart, blood cell counts, pancreas function, liver function, and electrolytes., Tasigna can increase the risk for tumor lysis syndrome (TLS), which is caused by the rapid breakdown of cancer cells. Your doctor may order blood tests to determine if you have TLS. TLS can lead to kidney impairment and/or an abnormal heartbeat., Bleeding and death have been reported during treatment with Tasigna. Contact your doctor immediately if you have uncontrollable bleeding, vision changes, unconsciousness, sudden confusion, or sudden headache., Tasigna use may cause your body to accumulate excess fluid. Tell your doctor if you have shortness of breath, swelling, or rapid weight gain., Tasigna may affect the growth and development in children with chronic phase PH+ CML and should be monitored., Tell your doctor if you are pregnant, suspect that you are pregnant, or plan to become pregnant. Tasigna may cause harmful adverse effects to an unborn baby. Birth control should be used while you take Tasigna and for at least 2 weeks after your final dose of Tasigna., Tell your doctor if you are breastfeeding or plan to start breastfeeding. Do not breastfeed while you are taking Tasigna and for at least two weeks after your final dose of Tasigna.
